Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced it has received approval to implement a variation to the Yescarta® (axicabtagene ciloleucel) Marketing Authorization from the European Medicine Agency (EMA) for end-to-end manufacturing. With this approval, Kite’s European manufacturing facility, designed and dedicated to the manufacture of individualized cell therapies, is now fully operational. “Kite is focused foremost on the needs of patients livin
